Akorn Stock Price, News & Analysis (NASDAQ:AKRX)

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.09. The business earned $178 million during the quarter, compared to the consensus estimate of $171.97 million. Akorn had a negative return on equity of 17.88% and a negative net margin of 72.25%. The firm's revenue for the quarter was down 6.8% compared to the same quarter last year. View Akorn's Earnings History.

Akorn is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Akorn.

Akorn will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Akorn updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $692.99 million.

4 equities research analysts have issued 12 month price targets for Akorn's shares. Their predictions range from $4.00 to $11.00. On average, they anticipate Akorn's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 46.8% from the stock's current price. View Analyst Price Targets for Akorn.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.

Media coverage about AKRX stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Akorn.

Akorn saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 10,920,000 shares, a drop of 13.0% from the August 30th total of 12,550,000 shares. Based on an average daily volume of 1,920,000 shares, the short-interest ratio is currently 5.7 days. Approximately 11.6% of the shares of the company are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by many different of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.18%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.03%), Moors & Cabot Inc. (0.02%) and CIBC Private Wealth Group LLC (0.01%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Akorn.

AKRX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Moors & Cabot Inc. and CIBC Private Wealth Group LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $4.77.

Akorn has a market capitalization of $600.30 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]